|
WO2020245450A1
|
|
Method for treatment of at risk patients
|
|
US2020297672A1
|
|
Methods of treatment of cholestatic diseases
|
|
US2020338047A1
|
|
Methods of treatment for cholestatic and fibrotic diseases
|
|
WO2020212522A1
|
|
Compositions and methods for the stabilization of micro-rna
|
|
WO2020208208A1
|
|
Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress
|
|
WO2020208205A1
|
|
Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
|
|
WO2020208044A1
|
|
Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
|
|
WO2020182952A1
|
|
Diagnosis of non-alcoholic steatohepatitis
|
|
WO2020127613A1
|
|
In vitro model of liver steatosis and fibrosing non-alcoholic steatohepatitis
|
|
WO2020025789A1
|
|
Elafibranor salts
|
|
US2019275146A1
|
|
Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
|
|
US2019083468A1
|
|
Methods of treatment for cholestatic and fibrotic diseases
|
|
KR20200090757A
|
|
Histological image automation pattern recognition and scoring method
|
|
US2020216901A1
|
|
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
|
|
WO2019053235A1
|
|
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
|
|
AU2018320715A1
|
|
Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
|
|
US2018280358A1
|
|
Methods of treatment for cholestatic and fibrotic diseases
|
|
EP3612175A1
|
|
Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
|
|
US2020061028A1
|
|
Pharmaceutical compositions for combination therapy
|
|
AU2018223976A1
|
|
Pharmaceutical compositions for combination therapy
|
